Par Pacific Holdings Inc
Change company Symbol lookup
Select an option...
PARR Par Pacific Holdings Inc
AOD Aberdeen Total Dynamic Dividend Fund
VIRX Viracta Therapeutics Inc
YELP Yelp Inc
CCLV Karbon-X Corp
NCBDF Bandai Namco Holdings Inc
GTN Gray Television Inc
BKD Brookdale Senior Living Inc
PMT PennyMac Mortgage Investment Trust
EVTVD Envirotech Vehicles Inc
Go

Energy : Oil, Gas & Consumable Fuels | Small Cap Value
Company profile

Par Pacific Holdings, Inc. owns and operates energy and infrastructure businesses. The Company operates through three segments: Refining, Retail and Logistics. Refining segment owns and operates approximately three refineries with total operating crude oil throughput capacity of over 154 thousand barrels per day (Mbpd) in Hawaii, Wyoming, and Washington. Retail segment includes retail outlets in Hawaii, Washington, and Idaho that sells gasoline, diesel and retail merchandise. Logistics segment owns and operates terminals, pipelines, a single point mooring (SPM), and trucking operations to distribute refined products throughout the islands of Oahu, Maui, Hawaii, Molokai, and Kauai. Its refinery in Newcastle, Wyoming, produces gasoline, jet fuel, ultra-low sulfur diesel (ULSD), and other associated refined products that are primarily marketed in Wyoming and South Dakota. It operates convenience stores at its Hawaii retail fuel outlets under its nomnom brand that sell merchandise.

Price
Delayed
$15.94
Day's Change
-0.62 (-3.74%)
Bid
--
Ask
--
B/A Size
--
Day's High
16.96
Day's Low
15.84
Volume
(Light)

Today's volume of 232,883 shares is on pace to be much lighter than PARR's 10-day average volume of 1,061,490 shares.

232,883

Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022

8:00 am ET April 26, 2022 (Globe Newswire) Print

Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 8872347. A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedical's website at www.talis.bio.

About Talis Biomedical

Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One system to enable accurate, low cost, and rapid molecular testing. The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for use of the Talis One COVID-19 Test System in a variety of healthcare settings. For more information, visit talisbio.com.

Contact

Media & Investors

Emily Faucette

ir@talisbio.com

415-595-9407

https://ml.globenewswire.com/media/333984f8-7701-4b9c-a5ce-a836bf670fa1/small/talis-vertical-logo-jpg.jpg

https://ml.globenewswire.com/media/333984f8-7701-4b9c-a5ce-a836bf670fa1/small/talis-vertical-logo-jpg.jpg

comtex tracking

COMTEX_406258305/2010/2022-04-26T08:00:09

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.